Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK+ Non-Small-Cell Lung Carcinoma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT07573696
What this trial is testing

Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy

Who this might be right for
Nonsmall Cell Lung Cancer Stage III
Wen-zhao ZHONG 50
Testing effectiveness (Phase 2)UnknownNCT04056572
What this trial is testing

Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
ALK-positive NSCLC
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 135
Not applicableStudy completedNCT03546894
What this trial is testing

Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Who this might be right for
Anaplastic Lymphoma Kinase-positiveCarcinoma Non-small-cell Lung
Takeda 111
Testing effectiveness (Phase 2)Study completedNCT02040870
What this trial is testing

LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 103
Testing effectiveness (Phase 2)Looking for participantsNCT05950139
What this trial is testing

Peptide Vaccine To Prevent Acquired Resistance In Patients With Advanced ALK+ NSCLC

Who this might be right for
NSCLC Stage IVALK Fusion Protein Expression
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 12
Testing effectiveness (Phase 2)Ended earlyNCT04211922
What this trial is testing

Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib

Who this might be right for
ALK-positive Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 4
Not applicableStudy completedNCT05167500
What this trial is testing

Efficacy & Safety Study of Lorlatinib in ALK/ROS1 Metastatic NSCLC Patients With Compassionate Use Treatment

Who this might be right for
Metastatic Non Small Cell Lung Cancer
Fundación GECP 118
Large-scale testing (Phase 3)Study completedNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Not applicableNo Longer AvailableNCT01947608
What this trial is testing

Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Study completedNCT01685138
What this trial is testing

LDK378 in Crizotinib naïve Adult Patients With ALK-activated Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 124
Early research (Phase 1)Study completedNCT02299505
What this trial is testing

Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 306
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Testing effectiveness (Phase 2)Study completedNCT03647488
What this trial is testing

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Novartis Pharmaceuticals 18
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Not applicableStudy completedNCT01700582
What this trial is testing

French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings

Who this might be right for
Carcinoma, Non-Small-Cell LungALK Gene MutationKRAS Gene Mutation+1 more
Intergroupe Francophone de Cancerologie Thoracique 17,664
Testing effectiveness (Phase 2)Active Not RecruitingNCT03808662
What this trial is testing

Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung

Who this might be right for
TNBC - Triple-Negative Breast CancerTriple Negative Breast CancerNSCLC+4 more
Memorial Sloan Kettering Cancer Center 107
Testing effectiveness (Phase 2)Study completedNCT04318938
What this trial is testing

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Who this might be right for
NSCLC
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 118
Early research (Phase 1)Active Not RecruitingNCT02393625
What this trial is testing

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

Who this might be right for
ALK-positive NSCLC
Novartis Pharmaceuticals 57
Not applicableUnknownNCT01637597
What this trial is testing

Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase Translocation

Who this might be right for
Non-small Cell Lung Cancer(NSCLC)
National Taiwan University Hospital 12
Not applicableNo Longer AvailableNCT03178071
What this trial is testing

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Who this might be right for
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
Next Page